Ȳ´ö»ó ¸íÀÇ

»ý¾ÖÁֱ⺰ Çѹæ Ä¡·á·Î ¿©¼º °Ç°­À» ÁöŰ´Â ¸®´õ

Ȳ´ö»ó ¸íÀÇ

  • ¼Ò ¼Ó
    °æÈñ´ëÇб³Çѹ溴¿ø
  • Áø·á°ú
    ÇÑÀÇÇÐ
  • Àü¹®ºÐ¾ß
    ºÒÀÓ, À¯»ê, »êÀü»êÈÄÁ¶¸®, »êÈÄdz, ¿ä½Ç±Ý, À¯¹æ¾Ï, Æó°æ±â Áúȯ ¹× Ç׳ëÈ­, ¿©¼º³ëÀμº Áúȯ

Ȳ´ö»ó ±³¼ö´Â »ý¾Ö Áֱ⺰ ¿©¼º ƯÀ¯ÀÇ »ý¸®Àû º¯È­¸¦ °í·ÁÇÑ ÀüÀÎÀû Ä¡·á¸¦ Áß¿ä½ÃÇÑ´Ù. ÁÖ¿ä Áø·á ºÐ¾ß´Â ºÒÀÓ°ú À¯»ê, »êÀü»êÈÄÁ¶¸®, »êÈÄdz, ¿ä½Ç±Ý, À¯¹æ¾Ï, Æó°æ±â Áúȯ ¹× Ç׳ëÈ­ µîÀÌ´Ù. ³­ÀÓ Ä¡·á¿Í À¯¹æ¾Ï ȯÀÚÀÇ »îÀÇ Áú Çâ»óÀ» À§ÇÑ ¿¬±¸¿¡ ÁÖ·ÂÇϰí ÀÖ´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • °æÈñ´ë ÇÑÀÇÇаú Çлç
  • °æÈñ´ë ÇÑÀÇÇаú ¼®»ç
  • °æÈñ´ë ÇÑÀÇÇаú ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) °æÈñ´ëÇб³Çѹ溴¿ø ÇѹæºÎÀΰú ±³¼ö

ÇÐȸȰµ¿

Academic activities
  • ´ëÇѾÏÇÑÀÇÇÐȸ ±³À°ÀÌ»ç
  • ´ëÇÑÇѹæºÎÀΰúÇÐȸ ÆíÁýÀÌ»ç
  • ´ëÇÑÅëÇÕ¾ÏÇÐȸ ÀÌ»ç
  • ´ëÇÑÇѹæºÎÀΰúÇÐȸ ÇмúÀÌ»ç
  • ´ëÇÑÇѹæºÎÀΰúÇÐȸ Ãѹ«ÀÌ»ç
ÀÓ»êºÎ¿¡°Ô »ç¿ëÇÒ ¼ö ÀÖ´Â ÇѹæÃ³¹æ
´ëÇ¥¼­Àû

ÀÓ»êºÎ¿¡°Ô »ç¿ëÇÒ ¼ö ÀÖ´Â ÇѹæÃ³¹æ

  • ÀúÀÚ(±Û)½Ã°Ô³ëŰ ¸¶»çÈ÷·Î(¹ø¿ª Ȳ´ö»ó)
  • ÃâÆÇ»ç°¡¿ÂÇØ¹Ìµð¾î
  • ¹ßÇàÀÏ2022³â 03¿ù 11ÀÏ
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 5°Ç
Á¦ ¸ñ ¿©¼ºÀ» À§ÇÑ ³» ¸ö ¼³¸í¼­
ÃâÆÇ»ç ¹ßÇàÀÏ 2021³â 12¿ù
Á¦ ¸ñ À¯¹æ¾ÏÀÇ º¸¿ÏÄ¡·á ÇÑÀÇÇ¥ÁØÀÓ»óÁø·áÁöħ
ÃâÆÇ»ç ¹ßÇàÀÏ 2021³â 11¿ù
Á¦ ¸ñ ¾Æ±â100ÀÏ, ¾ö¸¶ 100ÀÏ
ÃâÆÇ»ç ¹ßÇàÀÏ 2016³â 01¿ù
Á¦ ¸ñ Çѹ濩¼ºÀÇÇÐ
ÃâÆÇ»ç ¹ßÇàÀÏ 2012³â 02¿ù
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ ¿©¼º ³­ÀÓ°ú ÇÑÀÇÇÐ (´Ù³¶¼º³­¼ÒÁõÈıºÀ¸·Î ÀÎÇÑ ³­ÀÓÀÇ ÇÑ¾ç¹æ Ä¡·á)
¹ßÇ¥³âµµ 2022³â 11¿ù ¹ßÇ¥Áö
Á¦ ¸ñ ¹Ì½½Åä ÃßÃâ¹° Åõ¿©¿Í º´ÇàÇÑ ÇѹæÄ¡·á¸¦ ÅëÇØ È£ÀüµÈ Àç¹ß¼º ÀڱðæºÎ»óÇdz»Á¾¾ç Áõ·Êº¸°í
¹ßÇ¥³âµµ 2022³â 11¿ù ¹ßÇ¥Áö
Á¦ ¸ñ »êÈÄ À¯ÁóºÐºñºÎÀü¿¡ ´ëÇÑ ÀüħÀÇ È¿°ú: ü°èÀû ¹®Çå °íÂû
¹ßÇ¥³âµµ 2022³â ¹ßÇ¥Áö
Á¦ ¸ñ Analysis of Healthcare Utilization for Primary Dysmenorrhea in Korea: A Retrospective, Cross-Sectional Study
¹ßÇ¥³âµµ 2022³â ¹ßÇ¥Áö
Á¦ ¸ñ º¸Á¶»ý½Ä¼úÀ» ½ÃÇàÇÑ ³­ÀÓȯÀÚ¿¡¼­ÀÇ ¶ä Ä¡·á¿¡ ´ëÇÑ Ã¼°èÀû ¹®Çå°íÂû ¹× ¸ÞŸºÐ¼®
¹ßÇ¥³âµµ 2022³â ¹ßÇ¥Áö
Á¦ ¸ñ Combination of anti-PD-L1 antibody with peptide MEL-dKLA targeting M2 tumor-associated macrophages suppresses breast cancer metastasis
¹ßÇ¥³âµµ 2022³â ¹ßÇ¥Áö
Á¦ ¸ñ Therapeutic Effect of Melittin–dKLA Targeting Tumor-Associated Macrophages in Melanoma
¹ßÇ¥³âµµ 2022³â ¹ßÇ¥Áö

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°æÈñ´ëÇб³Çѹ溴¿ø

Àü¹®º´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
02-958-8114
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

°æÈñ´ëÇѹ溴¿øÀº ÀüÅë ÇÑÀÇÇаú Çö´ë ÀÇÇÐÀ» À¶ÇÕÇÑ ÅëÇÕ ÀÇ·á ¼­ºñ½º¸¦ Á¦°øÇÏ´Â º¸°Çº¹ÁöºÎ ÀÎÁõ Çѹ溴¿øÀÔ´Ï´Ù. ´Ù¾çÇÑ Àü¹® ºÐ¾ß¿¡¼­ ȯÀÚÀÇ Ã¼Áú°ú »óÅ¿¡ ¸ÂÃá ¸ÂÃãÇü Ä¡·á¸¦ ½ÃÇàÇÕ´Ï´Ù. ¸¸¼º Áúȯ ¹× ³­Ä¡¼º Áúȯ Ä¡·á¿¡ °­Á¡À» º¸À̸ç, ÀÚ¿¬ Ä¡À¯·ÂÀ» ±Ø´ëÈ­ÇÏ´Â Çѹæ Ä¡·á¹ýÀ» ÅëÇØ ȯÀÚµéÀÇ »îÀÇ ÁúÀ» ³ôÀÌ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

°æÈñ´ëÇб³Çѹ溴¿ø À̹ÌÁö

¼­¿ïƯº°½Ã µ¿´ë¹®±¸ °æÈñ´ë·Î 23 °æÈñ´ëÇб³Çѹ溴¿ø

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä